Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Esperion Therapeutics Inc's Business Segments
Esperion Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Product sales net
Total Revenue
$ 80
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product sales net54.2%
- Collaboration revenue45.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product sales net | $ 43 | 54.2% |
| Collaboration revenue | $ 37 | 45.8% |
Revenue by Product & Service Category - FY
- Product54.2%
- Collaboration Revenue45.8%
- Royalty Revenue From DSE and Sale of Bulk Tablets and Milestones Received40.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 43 | 54.2% |
| Collaboration Revenue | $ 37 | 45.8% |
| Royalty Revenue From DSE and Sale of Bulk Tablets and Milestones Received | $ 33 | 40.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product sales net54.2%
- Collaboration revenue45.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product sales net | $ 43 | 54.2% |
| Collaboration revenue | $ 37 | 45.8% |
Description of Esperion Therapeutics Inc
Esperion Therapeutics Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, that focuses on the discovery, development, and commercialization of novel therapies for the treatment of cardiovascular diseases. It was founded in 1998 by Roger Newton, who was also one of the co-founders of the renowned pharmaceutical company, the Parke-Davis Research Division of Warner-Lambert (now part of Pfizer).
The primary objective of Esperion Therapeutics is to improve cardiovascular health and reduce the risk of cardiovascular events, such as heart attacks and strokes, through the development of innovative lipid management therapies. The company specializes in developing small molecule drugs that target key enzymes and receptors involved in lipid metabolism and regulation.
Esperion’s flagship product is bempedoic acid, a first-in-class, oral, once-daily treatment that acts as an inhibitor of ATP Citrate Lyase (ACL), an enzyme crucial for the synthesis of cholesterol and fatty acids. By inhibiting ACL, bempedoic acid reduces the production of LDL cholesterol, the ad cholesterol linked to a higher risk of cardiovascular events. Bempedoic acid has shown promising results in clinical trials, demonstrating its efficacy in reducing LDL cholesterol levels when used alone or in combination with other lipid-lowering therapies.
In addition to bempedoic acid, Esperion Therapeutics is also developing a fixed-dose combination therapy called bempedoic acid/ezetimibe. This combination therapy combines the LDL-lowering effects of bempedoic acid with ezetimibe, a drug that inhibits cholesterol absorption in the intestines. The combination therapy has shown superior LDL cholesterol-lowering effects compared to either drug alone in clinical trials.
Esperion Therapeutics has a strong focus on research and development, with a dedicated team of scientists and researchers working on discovering and developing innovative therapies. The company holds a robust intellectual property portfolio, with numerous patents and patent applications related to its pipeline products and technologies.
Esperion Therapeutics has also established strategic partnerships and collaborations with other pharmaceutical companies, such as Daiichi Sankyo and Jeil Pharmaceutical, to further advance the development and commercialization of its pipeline products. These partnerships provide access to additional resources, capabilities, and expertise, enabling the company to accelerate the clinical development and global commercialization of its therapies.
The company's business strategy revolves around pursuing regulatory approvals for its pipeline products, followed by successful commercialization. They aim to provide patients with innovative treatment options that can complement existing therapies and improve overall cardiovascular health. Esperion Therapeutics' commercialization efforts focus on establishing strong partnerships with healthcare professionals, payors, and stakeholders to ensure broad market access and adoption of its therapies.
Overall, Esperion Therapeutics Inc. is a biopharmaceutical company that is dedicated to developing innovative therapies for the treatment of cardiovascular diseases. With their extensive research and development capabilities, pipeline of promising products, and strategic partnerships, Esperion is poised to make a significant impact in the field of lipid management and improve patient outcomes in the fight against cardiovascular diseases.
The primary objective of Esperion Therapeutics is to improve cardiovascular health and reduce the risk of cardiovascular events, such as heart attacks and strokes, through the development of innovative lipid management therapies. The company specializes in developing small molecule drugs that target key enzymes and receptors involved in lipid metabolism and regulation.
Esperion’s flagship product is bempedoic acid, a first-in-class, oral, once-daily treatment that acts as an inhibitor of ATP Citrate Lyase (ACL), an enzyme crucial for the synthesis of cholesterol and fatty acids. By inhibiting ACL, bempedoic acid reduces the production of LDL cholesterol, the ad cholesterol linked to a higher risk of cardiovascular events. Bempedoic acid has shown promising results in clinical trials, demonstrating its efficacy in reducing LDL cholesterol levels when used alone or in combination with other lipid-lowering therapies.
In addition to bempedoic acid, Esperion Therapeutics is also developing a fixed-dose combination therapy called bempedoic acid/ezetimibe. This combination therapy combines the LDL-lowering effects of bempedoic acid with ezetimibe, a drug that inhibits cholesterol absorption in the intestines. The combination therapy has shown superior LDL cholesterol-lowering effects compared to either drug alone in clinical trials.
Esperion Therapeutics has a strong focus on research and development, with a dedicated team of scientists and researchers working on discovering and developing innovative therapies. The company holds a robust intellectual property portfolio, with numerous patents and patent applications related to its pipeline products and technologies.
Esperion Therapeutics has also established strategic partnerships and collaborations with other pharmaceutical companies, such as Daiichi Sankyo and Jeil Pharmaceutical, to further advance the development and commercialization of its pipeline products. These partnerships provide access to additional resources, capabilities, and expertise, enabling the company to accelerate the clinical development and global commercialization of its therapies.
The company's business strategy revolves around pursuing regulatory approvals for its pipeline products, followed by successful commercialization. They aim to provide patients with innovative treatment options that can complement existing therapies and improve overall cardiovascular health. Esperion Therapeutics' commercialization efforts focus on establishing strong partnerships with healthcare professionals, payors, and stakeholders to ensure broad market access and adoption of its therapies.
Overall, Esperion Therapeutics Inc. is a biopharmaceutical company that is dedicated to developing innovative therapies for the treatment of cardiovascular diseases. With their extensive research and development capabilities, pipeline of promising products, and strategic partnerships, Esperion is poised to make a significant impact in the field of lipid management and improve patient outcomes in the fight against cardiovascular diseases.
Esperion Therapeutics Inc. is a biotechnology company primarily focused on developing innovative therapies for people with elevated levels of low-density lipoprotein cholesterol (LDL-C) – a significant risk factor for cardiovascular disease. The companys portfolio includes several segments, products, and services that are aimed at improving cardiovascular outcomes.
Segments
1. Research and Development
- Esperion is heavily invested in R&D to advance its pipeline of lipid-modifying therapies. The R&D segment is integral to understanding cholesterol metabolism, cardiovascular risk factors, and potential therapeutic targets. The focus is primarily on non-statin therapies, which offer alternative treatment options for patients who cannot tolerate statins.
2. Clinical Development
- The company conducts extensive clinical trials to assess the safety and efficacy of its products. This includes a variety of Phase 1, 2, and 3 trials to evaluate the pharmacodynamics, pharmacokinetics, and clinical outcomes associated with its therapies.
3. Commercial Operations
- Esperion also engages in commercial activities to bring its products to market. This includes marketing strategies, sales force deployment, partnerships with healthcare providers, and educational initiatives to improve awareness of cardiovascular disease and treatment options.
Products
1. Bempedoic Acid (Nexletol)
- Nexletol is one of Esperions flagship products, acting as an oral, once-daily medication that helps lower LDL-C levels. It is designed for patients who require additional LDL-C lowering beyond diet and statin therapy, or for those who cannot tolerate statins. Nexletol works by inhibiting ATP citrate lyase (ACL), an enzyme involved in cholesterol synthesis.
2. Bempedoic Acid/Ezetimibe Combination (Nexlizet)
- Nexlizet is a combination therapy that pairs bempedoic acid with ezetimibe, an established cholesterol absorption inhibitor. This dual-action approach provides a significant reduction in LDL-C levels for patients needing comprehensive therapeutic options. Nexlizet also offers a convenient once-daily dosing regimen.
Services
1. Patient Support Programs
- Esperion provides specialized programs designed to facilitate patient access and adherence to therapy. These initiatives may include cost assistance, educational resources, and personalized care plans to help patients manage their condition effectively.
2. Healthcare Provider Education
- The company actively engages in educating healthcare providers about cardiovascular health, LDL-C management, and its treatment offerings. This includes workshops, webinars, and informational materials tailored to current standards of care and new advancements in lipid therapies.
3. Collaborative Studies and Partnerships
- Esperion collaborates with academic and research institutions to advance scientific understanding and clinical practice regarding lipid management and cardiovascular disease. These partnerships help in conducting comprehensive studies and fostering innovation in therapeutic approaches.
Pipeline Products
Esperion is continuously working on developing additional therapies to advance its pipeline. This may involve next-generation lipid-lowering agents and combination therapies that serve as alternatives for patients not achieving their LDL-C goals.
Conclusion
Esperion Therapeutics Inc. is positioned to play a significant role in addressing cardiovascular health challenges through its focus on innovative treatments and comprehensive support services for both patients and healthcare providers. The combination and research efforts reflect the companys commitment to improving outcomes for those suffering from elevated cholesterol levels and associated cardiovascular risks.
Segments
1. Research and Development
- Esperion is heavily invested in R&D to advance its pipeline of lipid-modifying therapies. The R&D segment is integral to understanding cholesterol metabolism, cardiovascular risk factors, and potential therapeutic targets. The focus is primarily on non-statin therapies, which offer alternative treatment options for patients who cannot tolerate statins.
2. Clinical Development
- The company conducts extensive clinical trials to assess the safety and efficacy of its products. This includes a variety of Phase 1, 2, and 3 trials to evaluate the pharmacodynamics, pharmacokinetics, and clinical outcomes associated with its therapies.
3. Commercial Operations
- Esperion also engages in commercial activities to bring its products to market. This includes marketing strategies, sales force deployment, partnerships with healthcare providers, and educational initiatives to improve awareness of cardiovascular disease and treatment options.
Products
1. Bempedoic Acid (Nexletol)
- Nexletol is one of Esperions flagship products, acting as an oral, once-daily medication that helps lower LDL-C levels. It is designed for patients who require additional LDL-C lowering beyond diet and statin therapy, or for those who cannot tolerate statins. Nexletol works by inhibiting ATP citrate lyase (ACL), an enzyme involved in cholesterol synthesis.
2. Bempedoic Acid/Ezetimibe Combination (Nexlizet)
- Nexlizet is a combination therapy that pairs bempedoic acid with ezetimibe, an established cholesterol absorption inhibitor. This dual-action approach provides a significant reduction in LDL-C levels for patients needing comprehensive therapeutic options. Nexlizet also offers a convenient once-daily dosing regimen.
Services
1. Patient Support Programs
- Esperion provides specialized programs designed to facilitate patient access and adherence to therapy. These initiatives may include cost assistance, educational resources, and personalized care plans to help patients manage their condition effectively.
2. Healthcare Provider Education
- The company actively engages in educating healthcare providers about cardiovascular health, LDL-C management, and its treatment offerings. This includes workshops, webinars, and informational materials tailored to current standards of care and new advancements in lipid therapies.
3. Collaborative Studies and Partnerships
- Esperion collaborates with academic and research institutions to advance scientific understanding and clinical practice regarding lipid management and cardiovascular disease. These partnerships help in conducting comprehensive studies and fostering innovation in therapeutic approaches.
Pipeline Products
Esperion is continuously working on developing additional therapies to advance its pipeline. This may involve next-generation lipid-lowering agents and combination therapies that serve as alternatives for patients not achieving their LDL-C goals.
Conclusion
Esperion Therapeutics Inc. is positioned to play a significant role in addressing cardiovascular health challenges through its focus on innovative treatments and comprehensive support services for both patients and healthcare providers. The combination and research efforts reflect the companys commitment to improving outcomes for those suffering from elevated cholesterol levels and associated cardiovascular risks.